Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00104052
Recruitment Status : Completed
First Posted : February 23, 2005
Results First Posted : March 9, 2009
Last Update Posted : April 4, 2017
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The primary objective is to assess the safety, efficacy and tolerability of the combination of PEG-Intron plus REBETOL in pediatric subjects with chronic hepatitis C. The secondary objective is to measure the multiple-dose pharmacokinetics of PEG-Intron and REBETOL in pediatric subjects with chronic hepatitis C.

Condition or disease Intervention/treatment Phase
Hepatitis C, Chronic Biological: peginterferon alfa-2b (PEG2b) (SCH 54031) Drug: ribavirin (SCH 18908) Phase 3

Detailed Description:
This global, multicenter, open-label Phase 3 study will evaluate the safety, efficacy and tolerability of PEG-Intron plus REBETOL in previously untreated pediatric subjects, ages 3 through 17 years, with chronic hepatitis C.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 107 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron® Plus REBETOL® in Pediatric Patients With Chronic Hepatitis C
Study Start Date : February 2005
Actual Primary Completion Date : November 2007
Actual Study Completion Date : November 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: PEG-Intron alfa 2b (PEG2b) plus REBETOL (RBV)
PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) and RBV 400-1200 mg/day by mouth divided in 2 daily doses (administered twice daily with food, dosed 12 hours apart) for 48 weeks. Subjects treated up to 48 weeks and followed for additional 24 weeks after the end of treatment (total of 72 weeks study participation).
Biological: peginterferon alfa-2b (PEG2b) (SCH 54031)
PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) for 48 weeks.
Other Name: PEG-Intron (SCH 54031)
Drug: ribavirin (SCH 18908)
15 mg/kg/day for up to 48 weeks
Other Name: REBETOL (SCH 18908)

Primary Outcome Measures :
  1. Number of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment [ Time Frame: Up to 48-week treatment duration. Follow-up of 24 weeks. ]
    SVR is defined as undetectable hepatitis C virus ribonucleic acid (HCV-RNA) at 24 weeks post-treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   3 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children age 3-17 years old
  • Individuals weighing ≤ 90 kg
  • Previously untreated children with chronic hepatitis C (HCV RNA qPCR plasma positive)
  • Individuals with any HCV (hepatitis C virus) genotype
  • Hematology laboratory results of:

    • Hemoglobin (HGB) ≥ 11 g/dL for females or ≥ 12g/dL for males,
    • White Blood Cell Count (WBC) ≥ 3,000/mm^3,
    • Neutrophils ≥ 1,500/mm^3,
    • Platelets ≥ 100,000/mm^3
  • Chemistry laboratory results of:

    • Normal Thyroid Stimulating Hormone (TSH), albumin, creatinine, and Bilirubin,
    • Antinuclear antibody (ANA) ≤ 1:160,
    • Fasting Glucose 70-140 mg/dL. Note: If glucose levels are between 116-140 mg/dL or an individual has diabetes, HbA1C must be ≤ 8.5%
  • Compensated liver disease
  • Historic or pre-treatment liver biopsy slides available
  • No significant co-existing psychiatric disease
  • Those with diabetes, hypertension, or birth prior to 32 weeks gestational age must have normal eye exams and retinal photographs (these will be done as part of the study before hepatitis C treatment is given)
  • Patients and partners of patients willing to use adequate contraception during the course of the study
  • Abstain from alcohol and any other illicit drugs

Exclusion Criteria:

  • Serum ALT >10 times the upper limit of normal within the 6 months prior to study
  • Previous hepatitis C treatment
  • Children with liver disease not caused by hepatitis C
  • Most recent liver biopsy is normal
  • Individuals infected with the hepatitis B virus and/or human immunodeficiency virus (HIV)
  • Known blood disorders such as hemoglobinopathy, coagulopathy, or G6PD deficiency
  • Known immunodeficiency disorders requiring immunoglobulin therapy
  • Body organ transplant
  • Any known or suspected cancer within the past 5 years
  • Children with chronic pulmonary disease
  • Individuals who have a medical condition that would likely require systemic steroids
  • Those with a history of central nervous system (CNS) trauma or seizure disorders
  • Individuals with pre-existing psychiatric disorders including but not limited to moderate to severe depression
  • Current or previous use of lithium or antipsychotic drugs
  • Patients with clinically significant electrocardiogram (ECG) abnormalities and/or significant cardiovascular dysfunction (e.g., angina, congestive heart failure, recent myocardial infarction, uncontrolled hypertension, significant arrhythmia, cardiac sequelae from Kawasaki disease, cardiomyopathy, and/or history of congenital heart disease)
  • Insulin-dependent diabetes mellitus or poorly controlled non-insulin dependent diabetes mellitus
  • Immunologically mediated disease (e.g., inflammatory bowel disease [Crohn's disease, ulcerative colitis], rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, or symptomatic thyroid disorder)
  • History of substance abuse, including alcohol (e.g., binge drinking, blackouts), intravenous drugs and inhaled drugs
  • Subjects who have a history of pregnancy or who are pregnant and/or breast feeding. Subjects who intend to become pregnant during the study period. Subjects with partners who intend to become pregnant during the study period
  • Subjects with clinically significant retinal abnormalities such as known retinopathy of prematurity or other retinopathies

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00104052     History of Changes
Other Study ID Numbers: P02538: Part 1
First Posted: February 23, 2005    Key Record Dates
Results First Posted: March 9, 2009
Last Update Posted: April 4, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Peginterferon alfa-2b
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs